Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

Stroke Survivors Have Almost Three Times Higher Risk of Depression: A Systematic Review and Meta-Analysis

  • Naghedi, Aryan
  • Delgado-Mederos, Raquel
  • Vives-Bauza, Cristòfol
[eng] Background: Post-stroke depression (PSD) is one of the most frequent and important complications following stroke that adversely affects conditions such as functional recovery and the patient’s quality of life. Meanwhile, the prevalence proportion of PSD has been widely documented, ranging from 20 to 60%; the relationship between stroke and the manifestation of PSD, quantified with the odds ratio (OR), has been less explored. The primary aim of this meta-analysis is to determine the prevalence OR of suffering depression in stroke survivors. The prevalence proportion of PSD was also analyzed as a secondary aim. Methods: A pre-registered meta-analysis designed based on PRISMA guidelines with searches from inception to 23 September 2024 was carried out on PubMed, Web of Science, and SCOPUS databases. Studies reporting the prevalence OR associated with PSD manifestation were eligible for inclusion to achieve the primary aim. Twenty-six comparative studies, including a total population of 947,853 people, met the inclusion criteria. PSD prevalence proportion was extracted from 245 articles, including 493,681 stroke patients. Quality assessments were performed using the Newcastle–Ottawa Scale (NOS). Data were meta-analyzed using a random-effects model. Results: Compared with the control population, stroke survivors had higher odds of developing PSD (OR: 2.71; 95% CI: [2.29–3.22]). Prevalence of PSD was 34.46 ± 16.48. Conclusions: Stroke survivors have almost 3 times higher probability of suffering depression after stroke than the general population, and almost one third of stroke patients will suffer PSD.
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage

  • Núñez-Jurado, D.
  • Fernández-Vega, A.
  • Del Río, C.
  • Penalba, A.
  • Llucià-Carol, L.
  • Muiño-Acuña, E.
  • Ezcurra-Díaz, G.
  • Guasch-Jiménez, M.
  • Cullell, N.
  • Serrano-Heras, G.
  • Arias-Salazar, L.
  • Vives-Bauza, C.
  • Tur, S.
  • Urra, X.
  • Castellanos, M.
  • Krupinski, J.
  • Freijo-Guerrero, M.
  • Jiménez-Conde, J.
  • Fernández-Pérez, I.
  • Segura, T.
  • Marti-Fabregas, J.
  • Férnandez-Cadenas, I.
  • Montaner, J.
[eng] Background: Timely differentiation between ischemic stroke (IS) and intracerebral hemorrhage (ICH) is critical for guiding appropriate acute management strategies. While neuroimaging is the diagnostic gold standard, its accessibility is often limited in urgent clinical settings. Blood biomarkers offer a promising, scalable diagnostic alternative; however, no validated panel is yet available for distinguishing stroke subtypes during the hyperacute phase. Methods: In a multicenter study, plasma samples were collected within 6 h of symptom onset. A total of 3,072 proteins were measured using Olink® proximity extension assays. We applied differential expression analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and receiver operating characteristic (ROC) curve evaluation. To interpret the biological relevance of the findings, we conducted functional enrichment and protein-protein interaction (PPI) analyses. Results: Among the 388 patients (344 IS, 44 ICH), 2,531 proteins were retained; 878 reached nominal significance (p < 0.05), and 67 remained significant after multiple-testing correction (FDR-adjusted p < 0.05). Of these, 844 were overexpressed in ICH and 34 in IS. GFAP, a glial marker, emerged as the most discriminative biomarker for ICH versus IS (AUC = 0.887; sensitivity: 80%, specificity: 90%), followed by BCAN (AUC = 0.820), SNAP25 (AUC = 0.797), and SPOCK1 (AUC = 0.786). For IS, S100A12 (AUC = 0.677) and MNDA (AUC = 0.657) showed the best performance. Multivariate analyses confirmed the presence of distinct proteomic patterns, with enrichment revealing a significant overrepresentation of neurodevelopmental and synaptic pathways. In PPI networks, GFAP and LYN emerged as central hubs. Conclusion: This study reveals a robust plasma proteomic signature distinguishing IS from ICH within hours of onset. These results lay the groundwork for scalable, blood-based diagnostics to guide early stroke management when imaging is delayed or unavailable.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke

  • Camps-Renom, Pol
  • Guasch-Jiménez, Marina
  • Álvarez-Cienfuegos, Juan
  • López-Hernández, Nicolás
  • Rodríguez-Campello, Ana
  • Tejada-Meza, Herbert
  • et al
Importance Optimal blood pressure (BP) management after successful endovascular therapy for acute ischemic stroke remains uncertain, as intensive lowering has shown no benefit or potential harm in prior trials. Objective To determine whether a reperfusion-guided systolic BP control strategy improves functional outcomes compared with guideline-recommended management after successful endovascular therapy for acute ischemic stroke. Design, Setting, and Participants This investigator-initiated, multicenter, prospective, randomized, open-label clinical trial with blinded end point assessment was conducted among adults with acute ischemic stroke due to anterior circulation large-vessel occlusion who achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2b) after endovascular therapy at 11 comprehensive stroke centers in Spain between June 14, 2021, and October 1, 2025, with 90-day follow-up. Data analysis was conducted from February 1 to March 12, 2026. Interventions Participants were randomly assigned (1:1) to a reperfusion-guided systolic BP strategy (140-160 mm Hg for mTICI score of 2b; 100-140 mm Hg for mTICI score of 2c/3) or guideline-recommended management (systolic BP <180 mm Hg) for 72 hours using antihypertensive agents or vasopressors as needed. Main Outcomes and Measures The primary outcome was a favorable functional outcome, defined as a modified Rankin Scale score of 0 to 2 at 90 days, assessed in the intention-to-treat population. Of 446 enrolled patients, 440 were included in the intention-to-treat analysis (mean age, 75 years; 53% women); 6 were excluded due to withdrawal or consent withdrawal. Results Among 440 patients (mean [SD] age, 75 [12] years; 233 [53.0%] women), 215 were assigned to the intervention group and 225 to the control group. At 90 days, 129 patients (60.0%) in the intervention group and 106 (47.1%) in the control group achieved a favorable functional outcome (absolute risk difference, 13.3%; 95% CI, 4.1%-22.6%; P = .005). Hemorrhagic transformation occurred in 48 patients (22.3%) in the intervention group and 71 (31.6%) in the control group (odds ratio, 0.62; 95% CI, 0.41-0.95). The rates of symptomatic intracranial hemorrhage (3.5% vs 3.9%) and 90-day mortality (15.4% vs 15.6%) did not differ between groups. Serious adverse events occurred in 34 patients (15.8%) in the intervention group and 27 (12.0%) in the control group. Conclusions and Relevance In this randomized clinical trial, a reperfusion-guided BP strategy improved functional outcomes and reduced hemorrhagic transformation without increasing major safety events, supporting a tailored approach to postthrombectomy BP management.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Transcriptomic profiling of thrombus-derived extracellular vesicles reveals PECAM-1 as a potential inflammatory marker for cardioembolic stroke patients

  • Machado, Florencio J.D.
  • Marta-Enguita, Juan
  • Herrera, María
  • Marta-Moreno, Javier
  • Páramo, José A.
  • Segura, Tomás
  • Serrano-Heras, Gemma
  • Hernández-Fernández, Francisco
  • Arias-Salazar, Lourdes
  • Yélamos-Sanz, Blanca
  • Zandio, Beatriz
  • Aymerich, Nuria
  • Muñoz, Roberto
  • Bermejo, Rebeca
  • Roncal Mancho, Carmen
  • Orbe, Josune
Accurate etiological diagnosis ensures appropriate secondary prevention of ischemic stroke (IS) patients. However, about 25–40% of IS cases remain of undetermined origin (referred to as ESUS if an unknown embolic source is suspected), highlighting the need to improve diagnostic precision. To identify potential biomarkers of IS etiologies, we analyzed the transcriptomic content of extracellular vesicles (EVs) from thrombi obtained after thrombectomy, including patients with cardioembolic (CE, n = 10), atherothrombotic (AT, n = 10) and ESUS (n = 10) IS (discovery cohort). mRNA levels of those differentially expressed genes in thrombus EVs were determined in microvascular brain endothelial cells after stimulation, revealing PECAM-1, as the most promising candidate. Next, PECAM-1 levels were determined in thrombi (n = 65) and serum samples (n = 95) of an independent validation cohort of IS patients, using immunohistochemistry and ELISA respectively. The transcriptome profiling and bioinformatics analysis revealed 1,514 gene transcripts in thrombus EVs, of which 114 were differentially expressed in AT vs CE etiologies. The genes upregulated in EVs from CE thrombi were enriched in pathways related to cell surface interactions at the vascular wall, leukocyte migration and neutrophil degranulation. Consistent with the increased PECAM-1 expression in thrombus EVs from CE vs AT etiologies, the endothelial expression of PECAM-1 increased after thrombin exposure and diminished upon atherogenic stimulation (oxLDL and TNFα). Moreover, thrombus expression of PECAM-1 was localized predominantly in platelet rich areas containing or surrounded by inflammatory cells and fibrin, and was higher in CE stroke thrombi. Serum levels of PECAM-1 were associated [OR (95%CI) 1.52 (1.14–2.03), p = 0.004] with the severity of stroke at Hospital admission. These findings collectively suggest that the transcriptional study of thrombus EVs may be useful to unravel the molecular pathways behind thrombus formation, and to explore local biological differences between IS etiologies. Specifically, PECAM-1, an adhesion molecule implicated in immuno-inflammatory processes, was increased in thrombi EVs and thrombi of patients with CE IS. Regarding the use of PECAM-1 as systemic biomarker, it did not discriminate IS etiologies, but was positively correlated with worse neurological outcome, suggesting a possible role of PECAM-1 in processes leading to brain injury post-IS., Red de Investigación Cooperativa Orientada a Resultados en Salud-Enfermedades Vasculares Cerebrales (RICORS-Ictus) RD21/0006/0008, RD24/0009/0028, and PI22/00436 financiado por el Instituto de Salud Carlos III, "Cofinanciado por la Unión Europea".